Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology

Frontiers in Oncology(2022)10.3389/fonc.2021.788245Source: DataRank Database

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology is a research paper published in Frontiers in Oncology (2022). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.68)OA: goldTopics (26)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Yunan Nie ORCID,Dara L. Aisner ORCID,David Ross Camidge,Tejas Patil ORCID

Live enrichment

PubMed:35070994 PMC:PMC8777186 OpenAlex:https://openalex.org/W4206293846

National Institutes of Health

Grant: 3UL1TR002535-03S1

NIH Prior Approval Process Professional

National Institutes of Health

Grant: 3P50CA058187-18S1

Tissue Bank and Biomarkers Core

FWCI

0.68

Citation Percentile

0.7%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fonc.2021.788245/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fonc.2021.788245/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fonc.2021.788245/full

journalhttps://doi.org/10.3389/fonc.2021.788245

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35070994

Fields of Study

Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment03 medical and health sciences0302 clinical medicine

Keywords

PemetrexedMedicineLung cancerOncologyROS1Anaplastic lymphoma kinaseAdenosquamous carcinomaInternal medicinenon-small cell lung cancer (NSCLC)HistologyCancerChemotherapyAdenocarcinomaCancer researchCisplatinnon-small-cell lung canceralkSquamousAdenosquamousNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology

FAIR Checklist

Authors (4)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)